Greg Madison CEO of Shield Therapeutics discusses their strong Q2 which showed total prescriptions for Accrufer® increase by 50% compared to Q1 and says, “There is a very substantial market opportunity for Accrufer® and we are looking to identify ways to maximise the momentum we are building in order to further drive continued Accrufer® growth”
Highlights
Snapshot of increasing Q2 KPI metrics - (all comparisons are sequential to Q1 2023)
· Increase in total prescriptions -- Over 15,800, grew 50%
o May grew 28% vs April, and June grew 30% vs May
· Increase in new prescriptions - grew 63%
· Increase in first time writers - grew 157%
· Positive clinical experiences leading to follow-up prescriptions
o High percentage of repeat writers - 73% of the HCP's who wrote an Rx in Q1 '23 wrote another prescription in Q2